dog |
LD |
oral |
> 2gm/kg (2000mg/kg) |
? |
Gekkan Yakuji. Pharmaceuticals Monthly. Vol. 35, Pg. 387, 1993. |
mouse |
LD50 |
intraperitoneal |
> 5gm/kg (5000mg/kg) |
BEHAVIORAL: CHANGES IN MOTOR ACTIVITY (SPECIFIC ASSAY)
BEHAVIORAL: MUSCLE WEAKNESS
KIDNEY, URETER, AND BLADDER: OTHER CHANGES |
Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 18(Suppl, |
mouse |
LD50 |
oral |
> 5gm/kg (5000mg/kg) |
KIDNEY, URETER, AND BLADDER: OTHER CHANGES |
Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 18(Suppl, |
mouse |
LD50 |
subcutaneous |
> 5gm/kg (5000mg/kg) |
? |
Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 18(Suppl, |
mouse |
LDLo |
intravenous |
75mg/kg (75mg/kg) |
SENSE ORGANS AND SPECIAL SENSES: PTOSIS: EYE
LUNGS, THORAX, OR RESPIRATION: RESPIRATORY DEPRESSION
BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) |
Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 24, Pg. 905, 1996. |
rat |
LD50 |
intraperitoneal |
5gm/kg (5000mg/kg) |
BEHAVIORAL: CHANGES IN MOTOR ACTIVITY (SPECIFIC ASSAY)
BEHAVIORAL: MUSCLE WEAKNESS
LUNGS, THORAX, OR RESPIRATION: RESPIRATORY DEPRESSION |
Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 18(Suppl, |
rat |
LD50 |
oral |
> 5gm/kg (5000mg/kg) |
? |
Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 18(Suppl, |
rat |
LD50 |
subcutaneous |
> 5gm/kg (5000mg/kg) |
? |
Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 18(Suppl, |
rat |
LDLo |
intravenous |
58mg/kg (58mg/kg) |
BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)
BEHAVIORAL: ATAXIA
LUNGS, THORAX, OR RESPIRATION: RESPIRATORY DEPRESSION |
Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 24, Pg. 905, 1996. |